Focus: Compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in MS patients
Progentos Therapeutics is a life sciences company focused on Compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in MS patients.
Funding Stage
PUBLIC
Open Jobs
0
Open Jobs (0)
No open positions listed yet.